MeSH D003930 - diabetic retinopathy
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Bayer | Aflibercept | Eylea |  | 2012-11-21 |  |  |
| Biocon | Aflibercept | Yesafili |  | 2024-05-20 |  |  |
| Genentech | Ranibizumab | Lucentis |  | 2006-06-30 |  |  |
| Ranibizumab | Susvimo |  | 2021-10-22 |  |  | |
| Faricimab | Vabysmo |  | 2022-01-28 |  |  | |
| Midas Pharma | Ranibizumab | Ranivisio |  | 2022-08-25 |  |  |
| Novartis | Ranibizumab | Lucentis |  | 2007-01-22 | $1,722 M | Q2/21-Q2/24 |
| Regeneron Pharmaceuticals | Aflibercept | Eylea |  | 2011-11-18 | $5,217.8 M | Q3/23-Q2/24 |
| Roche | Faricimab | Vabysmo |  | 2022-09-15 | $2,221.9 M | Q4/22-Q3/23 |
| Samsung Bioepis | Ranibizumab | Byooviz |  | 2021-09-17 |  |  |
| Sandoz | Ranibizumab | Cimerli |  | 2022-08-02 |  |  |
1
2
>
Clinical Trials
Historical Success Rate
Phase 1
50%12/24
Phase 2
50%17/34
Phase 3
44%14/32
Approved: 5Overall Success rate: 11%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use